Posted by Michael Wonder on 27 Mar 2025
Savara completes submission of the biologics license application to the US FDA for Molbreevi as a treatment for auto-immune pulmonary alveolar proteinosis
26 March 2025 - Priority review was requested, commercial launch preparations ynderway.
Savara today announced that it has completed submission of the BLA to the FDA for Molbreevi as a treatment for auto-immune pulmonary alveolar proteinosis.
